FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891072599> ?p ?o ?g. }

• W2891072599 abstract "Dual antiplatelet treatment with aspirin and clopidogrel is the standard therapy for patients undergoing percutaneous coronary intervention (PCI). However, a portion of patients suffer from clopidogrel resistance (CR) and consequently with recurrence of cardiovascular events. Genetic factors such as loss-of-function variants of CYP2C19 contribute a lot to CR. Recently, the N-6-adenine-specific DNA methyltransferase 1 (N6AMT1) rs2254638 polymorphism is reported to be associated with clopidogrel response. To validate the association between N6AMT1 rs2254638 polymorphism and clopidogrel response, 435 Chinese CAD patients receiving aspirin and clopidogrel were recruited. N6AMT1 rs2254638 and CYP2C19*2/*3 polymorphisms were genotyped. Platelet reaction index (PRI) was measured by VASP-phosphorylation assay after treated with a 300 mg loading dose (LD) clopidogrel or 75 mg daily maintenance dose (MD) clopidogrel for at least 5 days. There was a significant difference in PRI between LD cohort and MD cohort. Carriers of CYP2C19*2 allele showed significantly increased PRI in the entire cohort and in respective of the MD and LD cohorts (p < 0.001, p = 0.003, p < 0.001, respectively). However, carriers of CYP2C19*3 allele exhibited significantly higher PRI only in the entire cohort and LD cohort (p = 0.023, p = 0.023 respectively). PRI value was significantly higher in CYP2C19 PM genotyped patients as compared with those carrying the IM genotypes and EM genotype (p < 0.001). Besides, carriers of the rs2254638 C allele showed significantly higher PRI in entire cohort and in the LD cohort (p = 0.023, p = 0.008, respectively). When the patients were grouped into clopidogrel resistance (CR) and non-clopidogrel resistance (non-CR) groups, CYP2C19*2 was associated with increased risk of CR in the entire cohort, the LD cohort and the MD cohort (p < 0.001, p < 0.001, and p = 0.019, respectively). Carriers of the rs2254638 C allele also showed increased risk of CR in the entire cohort and the LD cohort (p = 0.024, and p = 0.028, respectively). N6AMT1 rs2254638 remained as a strong predictor for CR (TC vs. TT: OR = 1.880, 95% CI = 1.099-3.216,p = 0.021; CC vs. TT: OR = 1.930, 95% CI = 1.056-3.527, p = 0.032; TC + CC vs. TT: OR = 1.846, 95%CI = 1.126-3.026, p = 0.015) after adjustment for confounding factors. Our study confirmed the influence of CYP2C19*2 and rs2254638 polymorphisms on clopidogrel resistance in Chinese CAD patients. Both CYP2C19*2 and N6AMT1 rs2254638 polymorphism may serve as independent biomarkers to predict CR." @default.
• W2891072599 created "2018-09-27" @default.
• W2891072599 creator A5013719120 @default.
• W2891072599 creator A5017856049 @default.
• W2891072599 creator A5027931376 @default.
• W2891072599 creator A5034237051 @default.
• W2891072599 creator A5035886812 @default.
• W2891072599 creator A5045206097 @default.
• W2891072599 creator A5053087783 @default.
• W2891072599 creator A5074866383 @default.
• W2891072599 creator A5077034623 @default.
• W2891072599 creator A5091070290 @default.
• W2891072599 date "2018-09-19" @default.
• W2891072599 modified "2023-09-26" @default.
• W2891072599 title "Association of N6AMT1 rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease" @default.
• W2891072599 cites W1409766979 @default.
• W2891072599 cites W1963548002 @default.
• W2891072599 cites W1985059672 @default.
• W2891072599 cites W1985798331 @default.
• W2891072599 cites W1990228066 @default.
• W2891072599 cites W1993518253 @default.
• W2891072599 cites W2009019293 @default.
• W2891072599 cites W2014706503 @default.
• W2891072599 cites W2016031125 @default.
• W2891072599 cites W2032424975 @default.
• W2891072599 cites W2034031223 @default.
• W2891072599 cites W2041694866 @default.
• W2891072599 cites W2057506947 @default.
• W2891072599 cites W2058874291 @default.
• W2891072599 cites W2063841367 @default.
• W2891072599 cites W2067629047 @default.
• W2891072599 cites W2082149672 @default.
• W2891072599 cites W2084986504 @default.
• W2891072599 cites W2089747160 @default.
• W2891072599 cites W2099022345 @default.
• W2891072599 cites W2099167511 @default.
• W2891072599 cites W2108790161 @default.
• W2891072599 cites W2135575592 @default.
• W2891072599 cites W2137908623 @default.
• W2891072599 cites W2148633205 @default.
• W2891072599 cites W2149465085 @default.
• W2891072599 cites W2154940301 @default.
• W2891072599 cites W2167508909 @default.
• W2891072599 cites W2345636095 @default.
• W2891072599 cites W2400928599 @default.
• W2891072599 cites W2519966276 @default.
• W2891072599 cites W2553125603 @default.
• W2891072599 cites W2567280222 @default.
• W2891072599 cites W2596392808 @default.
• W2891072599 cites W2599591481 @default.
• W2891072599 cites W2602126461 @default.
• W2891072599 cites W2606131460 @default.
• W2891072599 cites W2652286378 @default.
• W2891072599 cites W2774265477 @default.
• W2891072599 cites W2791453970 @default.
• W2891072599 cites W4293084779 @default.
• W2891072599 doi "https://doi.org/10.3389/fphar.2018.01039" @default.
• W2891072599 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6156268" @default.
• W2891072599 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30283338" @default.
• W2891072599 hasPublicationYear "2018" @default.
• W2891072599 type Work @default.
• W2891072599 sameAs 2891072599 @default.
• W2891072599 citedByCount "9" @default.
• W2891072599 countsByYear W28910725992020 @default.
• W2891072599 countsByYear W28910725992021 @default.
• W2891072599 countsByYear W28910725992022 @default.
• W2891072599 countsByYear W28910725992023 @default.
• W2891072599 crossrefType "journal-article" @default.
• W2891072599 hasAuthorship W2891072599A5013719120 @default.
• W2891072599 hasAuthorship W2891072599A5017856049 @default.
• W2891072599 hasAuthorship W2891072599A5027931376 @default.
• W2891072599 hasAuthorship W2891072599A5034237051 @default.
• W2891072599 hasAuthorship W2891072599A5035886812 @default.
• W2891072599 hasAuthorship W2891072599A5045206097 @default.
• W2891072599 hasAuthorship W2891072599A5053087783 @default.
• W2891072599 hasAuthorship W2891072599A5074866383 @default.
• W2891072599 hasAuthorship W2891072599A5077034623 @default.
• W2891072599 hasAuthorship W2891072599A5091070290 @default.
• W2891072599 hasBestOaLocation W28910725991 @default.
• W2891072599 hasConcept C104317684 @default.
• W2891072599 hasConcept C126322002 @default.
• W2891072599 hasConcept C135763542 @default.
• W2891072599 hasConcept C140840227 @default.
• W2891072599 hasConcept C180754005 @default.
• W2891072599 hasConcept C2777628954 @default.
• W2891072599 hasConcept C2777849778 @default.
• W2891072599 hasConcept C2778213512 @default.
• W2891072599 hasConcept C2780400711 @default.
• W2891072599 hasConcept C500558357 @default.
• W2891072599 hasConcept C526171541 @default.
• W2891072599 hasConcept C54355233 @default.
• W2891072599 hasConcept C62231903 @default.
• W2891072599 hasConcept C71924100 @default.
• W2891072599 hasConcept C72563966 @default.
• W2891072599 hasConcept C86803240 @default.
• W2891072599 hasConcept C90924648 @default.
• W2891072599 hasConcept C98274493 @default.
• W2891072599 hasConceptScore W2891072599C104317684 @default.
• W2891072599 hasConceptScore W2891072599C126322002 @default.
• W2891072599 hasConceptScore W2891072599C135763542 @default.

• next